104 related articles for article (PubMed ID: 38871976)
1. Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma.
Sanagawa A; Hayakawa T; Yamamoto A; Hotta Y; Furukawa-Hibi Y; Morita A
Drugs R D; 2024 Jun; ():. PubMed ID: 38871976
[TBL] [Abstract][Full Text] [Related]
2. Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma.
Sanagawa A; Hayakawa T; Nishida E; Yamamoto A; Ikumi K; Mori Y; Hotta Y; Kimura K; Furukawa-Hibi Y; Morita A
J Dermatol; 2023 Jul; 50(7):917-926. PubMed ID: 37041679
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma.
Morita A; Tateishi C; Ikumi K; Hayashi D; Nakada A; Nishihara H; Torii K; Nishida E; Tsuruta D
Dermatol Ther (Heidelb); 2022 Mar; 12(3):615-629. PubMed ID: 35084694
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
Hamada T; Tokura Y; Sugaya M; Ohtsuka M; Tsuboi R; Nagatani T; Kiyohara E; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Saida T; Iwatsuki K
J Dermatol; 2019 Jul; 46(7):557-563. PubMed ID: 31090237
[TBL] [Abstract][Full Text] [Related]
5. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.
Hamada T; Morita A; Suga H; Boki H; Fujimura T; Hirai Y; Shimauchi T; Tateishi C; Kiyohara E; Muto I; Nakajima H; Abe R; Fujii K; Nishigori C; Nakano E; Yonekura K; Funakoshi T; Amano M; Miyagaki T; Makita N; Manaka K; Shimoyama Y; Sugaya M
J Dermatol; 2022 Feb; 49(2):253-262. PubMed ID: 34658060
[TBL] [Abstract][Full Text] [Related]
7. Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene.
Cabello I; Alia P; Pintó X; Muniesa C; Fernandez-de-Misa R; Peñate Y; Morillo M; Perez-Farriols A; Estrach T; Izu R; Gallardo F; Román C; Cervigón I; Ortiz-Brugues A; Ortiz-Romero PL; Servitje O
JAMA Dermatol; 2018 Dec; 154(12):1424-1431. PubMed ID: 30422238
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
11. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
12. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.
Fujimura T; Sato Y; Tanita K; Amagai R; Shimauchi T; Ogata D; Fukushima S; Miyashita A; Fujisawa Y; Kambayashi Y; Aiba S
J Dermatol; 2020 Jun; 47(6):636-640. PubMed ID: 32207181
[TBL] [Abstract][Full Text] [Related]
13. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):T547-T554. PubMed ID: 38653368
[TBL] [Abstract][Full Text] [Related]
14. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Cabello I; Servitje O; Corbella X; Bardés I; Pintó X
Clin Exp Dermatol; 2017 Apr; 42(3):276-281. PubMed ID: 28233333
[TBL] [Abstract][Full Text] [Related]
16. Bexarotene in the treatment of cutaneous T-cell lymphoma.
Querfeld C; Nagelli LV; Rosen ST; Kuzel TM; Guitart J
Expert Opin Pharmacother; 2006 May; 7(7):907-15. PubMed ID: 16634713
[TBL] [Abstract][Full Text] [Related]
17. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy.
Sato Y; Fujimura T; Kambayashi Y; Hashimoto A; Aiba S
Case Rep Oncol; 2018; 11(1):212-215. PubMed ID: 29681823
[TBL] [Abstract][Full Text] [Related]
19. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
20. Bexarotene-Induced Hypertriglyceridemia: A Case Report.
Maminakis C; Whitman AC; Islam N
Case Rep Oncol; 2018; 11(1):234-238. PubMed ID: 29805374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]